Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)–dependent migration and homing in multiple myeloma

Blood (2006) 109 (7): 2708–2717.

https://doi.org/10.1182/blood-2006-07-035857

Published: 2006

Journal Articles

Herpes-Simplex Thymidine Kinase Gene as a Selective Marker in Evaluating the Bone Marrow Microenvironment in Multiple Myeloma (MM).

Alissa Huston, MD, Ganwei Lu, MD, Judy Anderson, BS, Ken Patrene, BS, Lily Hong, MD, Lori Ehrlich, PhD, David Roodman, MD, PhD

Blood (2006) 108 (11): 510.

https://doi.org/10.1182/blood.V108.11.510.510

Published: 2006

Journal Articles

Molecular Mechanisms Regulating Migration and Adhesion in Response to the Chemokine SDF-1 in Multiple Myeloma (MM).

Irene Ghobrial, MD, Ujjal Singha, PhD, Yazan Alsayed, MD, Alissa Huston, MD, Lanie Francis, MD, Ganwei Lu, MD, Judy Anderson, Suzanne Lentzsch, MD, G. David Roodman, MD, PhD

Blood (2005) 106 (11): 2491.

https://doi.org/10.1182/blood.V106.11.2491.2491

Published: 2005

Journal Articles

Differential Response to Proteosome Inhibition in EBV Positive and Negative Lymphoma Cell Lines: Clinical Implications in Post Transplant Lymphoproliferative Disorders (PTLD).

Yazan Alsayed, MD, Ujjal Singha, PhD, Lanie Francis, MD, Alissa Huston, MD, Ganwei Lu, MD, Judy Anderson, Suzanne Lentzsch, MD, G. David Roodman, MD, PhD, Irene Ghobrial, MD

Blood (2005) 106 (11): 2413.

https://doi.org/10.1182/blood.V106.11.2413.2413

Published: 2005

Journal Articles

Combination of the mTOR Inhibitor Rapamycin with the HSP90 Inhibitor 17-AAG Has Synergistic Activity in EBV Positive Post Transplant Lymphoproliferative Disorders (PTLD).

Yazan Alsayed, MD, Ujjal Singha, PhD, Lanie Francis, MD, Alissa Huston, MD, Ganwei Lu, MD, Judy Anderson, Suzanne Lentzsch, MD, G. David Roodman, MD, PhD, Irene M. Ghobrial, MD

Blood (2005) 106 (11): 2414.

https://doi.org/10.1182/blood.V106.11.2414.2414

Published: 2005

Journal Articles

Proteomic Analysis Identifies Differences in Multiple Myeloma (MM) Cells Sensitive and Resistant to AKT Inhibition.

Alissa Huston, MD, Alexey Leontovich, MD, Michael Timm, MD, Yazan Alsayed, MD, Ujjal Singha, PhD, Lanie Francis, MD, Ganwei Lu, PhD, Judy Anderson, Suzanne Lentzsch, MD, Irene Ghobrial, MD

Blood (2005) 106 (11): 3402.

https://doi.org/10.1182/blood.V106.11.3402.3402

Published: 2005

Journal Articles

The Role of the AKT Inhibitor Perifosine in Migration and Adhesion in Multiple Myeloma (MM).

Alissa Huston, MD, Ujjal Singha, PhD, Yazan Alsayed, MD, Lanie Francis, MD, Ganwei Lu, MD, Judy Anderson, Suzanne Lentzsch, MD, G. David Roodman, MD, PhD, Irene M. Ghobrial, MD

Blood (2005) 106 (11): 2509.

https://doi.org/10.1182/blood.V106.11.2509.2509

Published: 2005

Journal Articles

Proteomic Analysis of Waldenstrom Macroglobulinemia (WM) Using Nanoscale Protein Micorarray Techniques.

Yazan Alsayed, MD, Michael Timm, MD, Alexey Leontovich, MD, Daniel Santos, MD, Allen Ho, MD, Ujjal Singha, PhD, Lanie Francis, MD, Alissa Huston, MD, Ganwei Lu, MD, Suzanne Lentzsch, MD, G. David Roodman, MD, PhD, Leleu Xavier, MD, Steven Treon, MD, PhD, Irene M. Ghobrial, MD

Blood (2005) 106 (11): 504.

https://doi.org/10.1182/blood.V106.11.504.504

Published: 2005

Journal Articles

Combination of the AKT Inhibitor Perifosine with the HSP90 Inhibitor 17-(Dimethylaminoethylamino)-17-Demethoxygeldanamycin (17-DMAG) Has Synergistic Activity in Multiple Myeloma (MM).

Alissa Huston, MD, Lanie Francis, MD, Yazan Alsayed, MD, Ujjal Singha, MD, Ganwei Lu, MD, Judy Anderson, Suzanne Lentzsch, MD, G. David Roodman, MD, PhD, Irene Ghobrial, MD

Blood (2005) 106 (11): 1592.

https://doi.org/10.1182/blood.V106.11.1592.1592

Published: 2005

NARROW

Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)–dependent migration and homing in multiple myeloma

Herpes-Simplex Thymidine Kinase Gene as a Selective Marker in Evaluating the Bone Marrow Microenvironment in Multiple Myeloma (MM).

Molecular Mechanisms Regulating Migration and Adhesion in Response to the Chemokine SDF-1 in Multiple Myeloma (MM).

Differential Response to Proteosome Inhibition in EBV Positive and Negative Lymphoma Cell Lines: Clinical Implications in Post Transplant Lymphoproliferative Disorders (PTLD).

Combination of the mTOR Inhibitor Rapamycin with the HSP90 Inhibitor 17-AAG Has Synergistic Activity in EBV Positive Post Transplant Lymphoproliferative Disorders (PTLD).

Proteomic Analysis Identifies Differences in Multiple Myeloma (MM) Cells Sensitive and Resistant to AKT Inhibition.

The Role of the AKT Inhibitor Perifosine in Migration and Adhesion in Multiple Myeloma (MM).

Proteomic Analysis of Waldenstrom Macroglobulinemia (WM) Using Nanoscale Protein Micorarray Techniques.

Combination of the AKT Inhibitor Perifosine with the HSP90 Inhibitor 17-(Dimethylaminoethylamino)-17-Demethoxygeldanamycin (17-DMAG) Has Synergistic Activity in Multiple Myeloma (MM).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only